Intranasal Administration of dsRNA Analog Poly(I:C) Induces Interferon-α Receptor-Dependent Accumulation of Antigen Experienced T Cells in the Airways

PLoS ONE

Volumn 7, Issue 12, 2012, Pages

  McNally, Beth ^a   Willette, Meredith ^a   Ye, Fang ^a   Partida Sanchez, Santiago ^a,b   Flaño, Emilio ^a,b  

^a THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN S HOSPITAL   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON RECEPTOR; ANTIGEN; POLYINOSINIC POLYCYTIDYLIC ACID; TOLL LIKE RECEPTOR 3;

AIRWAY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; LUNG; LYMPH NODE; LYMPHOCYTE MIGRATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PROTEIN INTERACTION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; TH1 CELL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; BROMODEOXYURIDINE; CELL PROLIFERATION; CHEMOKINES; CHEMOTAXIS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; LUNG; MICE; POLY I-C; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, INTERFERON ALPHA-BETA; RECEPTORS, PATTERN RECOGNITION; SIGNAL TRANSDUCTION; T-LYMPHOCYTES;

MUS; ORTHOMYXOVIRIDAE;

EID: 84870924942     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0051351     Document Type: Article

References (42)

1. Beutler B, (2004) Inferences, questions and possibilities in Toll-like receptor signalling. Nature 430: 257-263.
2. Kawai T, Akira S, (2010) The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 11: 373-384.
3. Wong JP, Christopher ME, Viswanathan S, Karpoff N, Dai X, et al. (2009) Activation of toll-like receptor signaling pathway for protection against influenza virus infection. Vaccine 27: 3481-3483.
4. Guerrero-Plata A, Baron S, Poast JS, Adegboyega PA, Casola A, et al. (2005) Activity and regulation of alpha interferon in respiratory syncytial virus and human metapneumovirus experimental infections. J Virol 79: 10190-10199.
5. Barnard DL, Day CW, Bailey K, Heiner M, Montgomery R, et al. (2006) Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB/c mice. Antivir Chem Chemother 17: 275-284.
6. Stahl-Hennig C, Eisenblatter M, Jasny E, Rzehak T, Tenner-Racz K, et al. (2009) Synthetic double-stranded RNAs are adjuvants for the induction of T helper 1 and humoral immune responses to human papillomavirus in rhesus macaques. PLoS Pathog 5: e1000373.
7. Isogawa M, Robek MD, Furuichi Y, Chisari FV, (2005) Toll-like receptor signaling inhibits hepatitis B virus replication in vivo. J Virol 79: 7269-7272.
8. Le Bon A, Schiavoni G, D'Agostino G, Gresser I, Belardelli F, et al. (2001) Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14: 461-470.
9. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, et al. (2005) Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433: 887-892.
10. Durand V, Wong SY, Tough DF, Le Bon A, (2006) IFN-alpha/beta-dependent cross-priming induced by specific toll-like receptor agonists. Vaccine 24 (Suppl 2): S2-22-23.
11. Ahonen CL, Doxsee CL, McGurran SM, Riter TR, Wade WF, et al. (2004) Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med 199: 775-784.
12. Ngoi SM, Tovey MG, Vella AT, (2008) Targeting poly(I:C) to the TLR3-independent pathway boosts effector CD8 T cell differentiation through IFN-alpha/beta. J Immunol 181: 7670-7680.
13. Lau YF, Tang LH, Ooi EE, (2009) A TLR3 ligand that exhibits potent inhibition of influenza virus replication and has strong adjuvant activity has the potential for dual applications in an influenza pandemic. Vaccine 27: 1354-1364.
14. Ichinohe T, Watanabe I, Ito S, Fujii H, Moriyama M, et al. (2005) Synthetic double-stranded RNA poly(I:C) combined with mucosal vaccine protects against influenza virus infection. J Virol 79: 2910-2919.
15. Ichinohe T, Ainai A, Tashiro M, Sata T, Hasegawa H, (2009) PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. Vaccine 27: 6276-6279.
16. Caskey M, Lefebvre F, Filali-Mouhim A, Cameron MJ, Goulet JP, et al. (2011) Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med 208: 2357-2366.
17. Atmar RL, Keitel WA, Cate TR, Munoz FM, Ruben F, et al. (2007) A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine 25: 5367-5373.
18. Wareing MD, Tannock GA, (2003) Route of administration is the prime determinant of IgA and IgG2a responses in the respiratory tract of mice to the cold-adapted live attenuated influenza A donor strain A/Leningrad/134/17/57. Vaccine 21: 3097-3100.
19. Ichinohe T, Ainai A, Ami Y, Nagata N, Iwata N, et al. (2010) Intranasal administration of adjuvant-combined vaccine protects monkeys from challenge with the highly pathogenic influenza A H5N1 virus. J Med Virol 82: 1754-1761.
20. Ichinohe T, Kawaguchi A, Tamura S, Takahashi H, Sawa H, et al. (2007) Intranasal immunization with H5N1 vaccine plus Poly I:Poly C12U, a Toll-like receptor agonist, protects mice against homologous and heterologous virus challenge. Microbes Infect 9: 1333-1340.
21. Li H, Nookala S, Re F, (2007) Aluminum hydroxide adjuvants activate caspase-1 and induce IL-1beta and IL-18 release. J Immunol 178: 5271-5276.
22. Longhi MP, Trumpfheller C, Idoyaga J, Caskey M, Matos I, et al. (2009) Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J Exp Med 206: 1589-1602.
23. Bonecchi R, Bianchi G, Bordignon PP, D'Ambrosio D, Lang R, et al. (1998) Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med 187: 129-134.
24. Sallusto F, Lenig D, Mackay CR, Lanzavecchia A, (1998) Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med 187: 875-883.
25. Kohlmeier JE, Miller SC, Smith J, Lu B, Gerard C, et al. (2008) The chemokine receptor CCR5 plays a key role in the early memory CD8+ T cell response to respiratory virus infections. Immunity 29: 101-113.
26. Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, et al. (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441: 101-105.
27. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA, (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413: 732-738.
28. Avril T, de Tayrac M, Leberre C, Quillien V, (2009) Not all polyriboinosinic-polyribocytidylic acids (Poly I:C) are equivalent for inducing maturation of dendritic cells: implication for alpha-type-1 polarized DCs. J Immunother 32: 353-362.
29. Shen E, Li L, Feng L, Lu L, Yao Z, et al. (2007) PIKA as an adjuvant enhances specific humoral and cellular immune responses following the vaccination of mice with HBsAg plus PIKA. Cell Mol Immunol 4: 113-120.
30. Dufour JH, Dziejman M, Liu MT, Leung JH, Lane TE, et al. (2002) IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168: 3195-3204.
31. Khan IA, MacLean JA, Lee FS, Casciotti L, DeHaan E, et al. (2000) IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection. Immunity 12: 483-494.
32. Agostini C, Calabrese F, Rea F, Facco M, Tosoni A, et al. (2001) Cxcr3 and its ligand CXCL10 are expressed by inflammatory cells infiltrating lung allografts and mediate chemotaxis of T cells at sites of rejection. Am J Pathol 158: 1703-1711.
33. Starkhammar M, Kumlien Georen S, Swedin L, Dahlen SE, Adner M, et al. (2012) Intranasal administration of poly(I:C) and LPS in BALB/c mice induces airway hyperresponsiveness and inflammation via different pathways. PLoS One 7: e32110.
34. Salaun B, Greutert M, Romero P, (2009) Toll-like receptor 3 is necessary for dsRNA adjuvant effects. Vaccine 27: 1841-1847.
35. Tough DF (2012) Modulation of T-cell function by type I interferon. Immunol Cell Biol.
36. Kolumam GA, Thomas S, Thompson LJ, Sprent J, Murali-Krishna K, (2005) Type I interferons act directly on CD8 T cells to allow clonal expansion and memory formation in response to viral infection. J Exp Med 202: 637-650.
37. Shiow LR, Rosen DB, Brdickova N, Xu Y, An J, et al. (2006) CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440: 540-544.
38. Avraamides G, Ng CY, David R, Gu Y, Fazekasova H, et al. (2007) IFN-alpha2 induces leukocyte integrin redistribution, increased adhesion, and migration. J Interferon Cytokine Res 27: 291-303.
39. Tough DF, Borrow P, Sprent J, (1996) Induction of bystander T cell proliferation by viruses and type I interferon in vivo. Science 272: 1947-1950.
40. Wiesel M, Crouse J, Bedenikovic G, Sutherland A, Joller N, et al. (2012) Type-I IFN drives the differentiation of short-lived effector CD8+ T cells in vivo. Eur J Immunol 42: 320-329.
41. Wiesel M, Kratky W, Oxenius A, (2011) Type I IFN substitutes for T cell help during viral infections. J Immunol 186: 754-763.
42. Flano E, Jewell NA, Durbin RK, Durbin JE (2009) Methods used to study respiratory virus infection. Curr Protoc Cell Biol Chapter 26: Unit 26 23.